Summary:
Researchers at the University of California San Diego have identified catestatin (CST), an endogenous peptide fragment, that in preclinical mouse models reduces both amyloid and tau accumulation, suppresses neuroinflammation, and improves cognitive and motor functions. Unlike single-target approaches, CST influences multiple interconnected disease pathways, suggesting a promising peptide-based strategy for complex neurodegenerative disorders such as Alzheimer’s disease.
Key Facts:
- Multi-target activity: In mouse models, CST treatment markedly reduced toxic aggregates of both tau and amyloid proteins while also lowering markers of chronic neuroinflammation.
- Functional improvements: Treated animals showed measurable gains in memory, learning, and motor coordination compared with untreated controls.
- Endogenous origin: CST is a natural cleavage product of chromogranin A, a protein involved in neurotransmitter storage and cellular signaling, and appears to influence brain energy metabolism and cellular resilience.
Source: University of California San Diego School of Medicine
Overview
Alzheimer’s disease and related dementias arise from a complex web of pathological processes rather than a single defect. Protein misfolding and aggregation (amyloid and tau), persistent neuroinflammation, metabolic dysfunction, and synaptic failure interact to drive progressive cognitive decline. Many experimental therapies target only one of these mechanisms. The UC San Diego team instead tested whether a naturally occurring peptide could act across several of these pathways.
The investigators focused on catestatin (CST), a peptide fragment derived from chromogranin A. In laboratory and animal experiments, CST not only reduced hallmark neuropathology but also protected neural circuits and improved behavior, suggesting effects beyond simple clearance of protein aggregates.
“Neurodegenerative diseases involve multiple interconnected problems — including misfolded proteins, neuroinflammation, and progressive dysfunction of brain cells,” said senior author Sushil K. Mahata, PhD. “Our findings show that CST can act across several disease-associated pathways to shift the brain toward a healthier state. Peptide-based therapies may offer a new approach to treating these complex disorders.”
Reducing Amyloid, Tau, and Neuroinflammation
To evaluate therapeutic potential, researchers administered CST to mouse models that reproduce key features of neurodegenerative decline. The treatment produced a range of structural and cellular benefits:
- Toxin clearance: CST significantly reduced the buildup of both amyloid plaques and tau aggregates, the two major protein pathologies associated with Alzheimer’s disease.
- Anti-inflammatory effects: The peptide lowered chronic neuroinflammatory signaling and reduced harmful immune activation in brain tissue.
- Behavioral recovery: Animals treated with CST performed better on memory and learning tasks and showed improved motor coordination relative to untreated animals.
Because chromogranin A participates in hormone and neurotransmitter packaging and release, CST already has known roles in cardiovascular, metabolic, and immune regulation. That systemic versatility appears to extend to the central nervous system, where CST modulates multiple protective processes rather than acting through a single receptor or pathway.
Cellular Resilience and Metabolic Support
Beyond clearing aggregates and damping inflammation, the team explored CST’s effects on neuronal bioenergetics. Early results indicate CST may influence how neurons produce and use energy, which could stabilize ATP production and help distressed cells maintain synaptic function under toxic stress.
“One exciting aspect of our findings is that CST may do more than reduce the pathological features of neurodegeneration,” said lead author Suborno Jati, PhD. “We are investigating whether CST can reshape brain energy metabolism to make neurons more resilient to the cellular stress associated with these diseases.”
By supporting energy generation and usage, CST could give vulnerable neurons the metabolic capacity needed to sustain communication and plasticity despite ongoing pathology.
The Path Forward
The authors emphasize these results are preclinical. Advancing CST or related peptide analogues into human trials will require extensive work to determine long-term safety, optimal dosing, mechanisms of delivery across the blood-brain barrier, and clinical efficacy. Nevertheless, the findings highlight the potential of peptide therapeutics to address the multifaceted biology of neurodegeneration.
Funding: Research support included grants from the National Institutes of Health and the U.S. Department of Veterans Affairs.
Mahata is the founder of CgA Therapeuticals, Inc. and co-founder of Siraj Therapeutics. Mahata and Jati are listed as co-inventors on intellectual property related to these findings.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this Genetics and Neuroregeneration Research
- Media contact: Miles Martin
- Source: UCSD
- Image credit: Image credited to Neuroscience News
- Original research (open access): Molecular Therapy (September 21, 2026). Title: “Catestatin peptide ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.” Authors: Suborno Jati, Satadeepa Kal, Daniel Munoz-Mayorga, Kechun Tang, Debashis Sahoo, Xu Chen, and Sushil K. Mahata.
- DOI: 10.1016/j.ymthe.2026.09.022
Abstract
Catestatin peptide ameliorates tauopathy and amyloidogenesis via adrenergic inhibition
Neurodegenerative disorders such as Alzheimer’s disease, corticobasal degeneration, and progressive supranuclear palsy are characterized by tau aggregation, neuroinflammation, and progressive cognitive decline. Metabolic dysregulation and imbalances in neuropeptides have been linked to these conditions, but the functional consequences and potential reversal of these imbalances remain incompletely understood.
Previous work identified chromogranin A (CgA) as a regulator of tau pathology. In this study, the authors investigated catestatin (CST), a peptide derived from CgA, for its role in modulating tauopathy. They report reduced CST levels and increased pancreastatin (PST) in affected brain regions from human cases and demonstrate that CST supplementation in neuronal cultures and organotypic slice cultures reduces tau phosphorylation and aggregation. In vivo, CST administration lowered pathological tau species, attenuated gliosis, improved cognitive measures in PS19 tauopathy mice, and reduced amyloid burden and neuroinflammation in 5xFAD mice.
Mechanistically, CST treatment reduced epinephrine levels in PS19 and 5xFAD mice, suppressed Protein Kinase A hyperactivation in PS19 and slice cultures, and linked CST deficiency with adrenergic stress signaling and tauopathy-mediated neurodegeneration, highlighting the therapeutic potential of CST supplementation.